Lifesci Capital Analysts Lift Earnings Estimates for Savara

Savara Inc. (NASDAQ:SVRA) – Stock analysts at Lifesci Capital upped their Q2 2026 earnings per share estimates for Savara in a report released on Sunday, March 15th. Lifesci Capital analyst F. Brisebois now forecasts that the company will post earnings of ($0.12) per share for the quarter, up from their prior estimate of ($0.13). The consensus estimate for Savara’s current full-year earnings is ($0.45) per share. Lifesci Capital also issued estimates for Savara’s FY2026 earnings at ($0.48) EPS.

Savara (NASDAQ:SVRA) last issued its quarterly earnings results on Friday, March 13th. The company reported ($0.13) earnings per share for the quarter, missing the consensus estimate of ($0.12) by ($0.01).

A number of other research analysts also recently commented on SVRA. HC Wainwright reiterated a “buy” rating on shares of Savara in a report on Monday. Oppenheimer set a $10.00 price target on Savara in a report on Tuesday, December 23rd. Wall Street Zen lowered shares of Savara from a “hold” rating to a “sell” rating in a research note on Saturday. Wells Fargo & Company raised their price objective on shares of Savara from $7.00 to $9.00 and gave the stock an “overweight” rating in a report on Thursday, December 18th. Finally, Guggenheim restated a “buy” rating on shares of Savara in a research report on Tuesday, December 23rd. One investment analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $9.00.

Savara Price Performance

Shares of SVRA opened at $5.15 on Wednesday. The company has a current ratio of 11.85, a quick ratio of 7.65 and a debt-to-equity ratio of 0.15. The firm’s fifty day simple moving average is $5.65 and its 200-day simple moving average is $4.99. The firm has a market capitalization of $1.05 billion, a price-to-earnings ratio of -9.72 and a beta of 0.31. Savara has a twelve month low of $1.89 and a twelve month high of $7.01.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the company. Prudential Financial Inc. acquired a new position in Savara in the 2nd quarter valued at $30,000. BNP Paribas Financial Markets lifted its position in Savara by 52.3% during the second quarter. BNP Paribas Financial Markets now owns 13,473 shares of the company’s stock worth $31,000 after buying an additional 4,626 shares during the period. Brevan Howard Capital Management LP acquired a new position in shares of Savara during the 2nd quarter valued at about $33,000. Russell Investments Group Ltd. lifted its holdings in shares of Savara by 930.5% during the 3rd quarter. Russell Investments Group Ltd. now owns 10,480 shares of the company’s stock worth $37,000 after acquiring an additional 9,463 shares during the period. Finally, Quadrature Capital Ltd purchased a new stake in Savara in the second quarter valued at approximately $42,000. Institutional investors and hedge funds own 87.93% of the company’s stock.

Key Headlines Impacting Savara

Here are the key news stories impacting Savara this week:

• Positive Sentiment: Lifesci Capital raised its Q2 2026 EPS forecast slightly (from ($0.13) to ($0.12)) and trimmed FY2026 loss expectations marginally (to ($0.48) from ($0.49)), signaling a small improvement in near-term outlook. MarketBeat SVRA
• Positive Sentiment: HC Wainwright maintained a “Buy” rating on SVRA, which supports investor demand and suggests confidence in Savara’s longer-term commercial potential despite model changes. MarketBeat SVRA
• Neutral Sentiment: HC Wainwright published detailed quarterly cadence estimates for 2026 (Q1–Q4) and multi-year projections that give investors updated milestones to watch, but these are expectations rather than new company results. MarketBeat SVRA
• Negative Sentiment: HC Wainwright cut FY2026 EPS to ($0.49) from ($0.39), increasing the near-term loss outlook and likely weighing on the stock as investors reassess cash runway and commercialization timing. MarketBeat SVRA
• Negative Sentiment: HC Wainwright lowered FY2027 and FY2028 forecasts (FY2027 to ($0.28) from ($0.16); FY2028 to $0.02 from $0.13), and also trimmed FY2029/FY2030 upside — these pushes out and reduce expected profitability, pressuring valuation that had factored in stronger long-term growth. MarketBeat SVRA

About Savara

Savara Inc (NASDAQ:SVRA) is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for rare respiratory diseases. The company specializes in in-licensing, advancing and potentially bringing to market novel treatments that address severe pulmonary conditions with high unmet medical need.

The company’s lead candidate, Molgradex (recombinant human granulocyte-macrophage colony-stimulating factor, or GM-CSF), is under regulatory review for the treatment of autoimmune pulmonary alveolar proteinosis (PAP), a rare lung disease characterized by the accumulation of surfactant.